Wells Fargo & Company MN Has $11.44 Million Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Wells Fargo & Company MN cut its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 11.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 863,678 shares of the company's stock after selling 114,324 shares during the quarter. Wells Fargo & Company MN's holdings in Takeda Pharmaceutical were worth $11,435,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of TAK. Blair William & Co. IL grew its holdings in Takeda Pharmaceutical by 8.1% in the 4th quarter. Blair William & Co. IL now owns 12,199 shares of the company's stock worth $162,000 after buying an additional 913 shares in the last quarter. Sage Rhino Capital LLC raised its stake in shares of Takeda Pharmaceutical by 14.9% during the fourth quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company's stock valued at $157,000 after purchasing an additional 1,538 shares in the last quarter. Aaron Wealth Advisors LLC lifted its holdings in Takeda Pharmaceutical by 7.2% in the fourth quarter. Aaron Wealth Advisors LLC now owns 25,000 shares of the company's stock worth $331,000 after purchasing an additional 1,670 shares during the period. OLD Mission Capital LLC grew its position in Takeda Pharmaceutical by 13.7% in the 4th quarter. OLD Mission Capital LLC now owns 13,977 shares of the company's stock valued at $185,000 after buying an additional 1,687 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in Takeda Pharmaceutical by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company's stock valued at $69,000 after buying an additional 1,770 shares during the period. Institutional investors own 9.17% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Price Performance

Shares of Takeda Pharmaceutical stock traded up $0.04 during trading on Friday, hitting $14.69. The stock had a trading volume of 1,971,072 shares, compared to its average volume of 1,850,668. The business has a fifty day moving average of $14.54 and a two-hundred day moving average of $13.91. The firm has a market cap of $46.73 billion, a P/E ratio of 36.71, a PEG ratio of 0.24 and a beta of 0.39. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.58 and a fifty-two week high of $15.37. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. On average, sell-side analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.